Baxter International Inc. BAX
NYSE · Healthcare · Medical - Instruments & Supplies
$25.39
Close on Fri, 20 Nov 2026 · market value $13.1B
What the price is betting on
Below its recordAt $25, the price assumes revenue shrinks about 6.6% a year for five years, from $11.6B to about $8.7B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.9% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than BAX? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$37
Base
$41
Bull
$45
Today $25
- Bear $37. Cash flow grows 0% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $41. Cash flow grows 2% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $45. Cash flow grows 4% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$11.4B$11.7B, on the path
- FY2027$10.7B$12B, on the path
- FY2028$9.9B$12.2B, on the path
- FY2029$9.3BNo estimate yet
- FY2030$8.7BThe full bet
Each year's revenue at −6.6% growth from $11.6B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Instruments & Supplies · listed on NYSE
- Revenue, FY2025
- $11.2B
- Growth, 3 years a year
- 4.2%
- Cash margin
- 2.9%
- Net debt
- $8B
- Shares, 3-year change
- +1.8%
- Dividend yield
- 2.6%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.